Regeneron: A Two-Bagger Before Tea Time?

by

Now, the concept of a “multibagger” – a stock that doubles your money, or more – is a curiously baseball-centric one. Peter Lynch, a man who once managed a great deal of other people’s money (a responsibility that, upon reflection, seems rather unsettling), coined the term. He imagined investors “running the bases,” which is all very well unless you happen to be a snail, or perhaps a particularly contemplative sloth. The point is, it’s about progress, and ideally, not getting tagged out by the market.)

Let’s consider Regeneron Pharmaceuticals (REGN +0.34%). It’s not exactly rocketing through the financial cosmos, having delivered a respectable, if somewhat understated, 106% gain over the last decade. But, and this is a rather important ‘but’, it possesses the potential to double your investment in the next few years. A “two-bagger,” as they say. Which is, logically, half a “four-bagger.” One must always consider the underlying mathematics.)

This potential isn’t conjured from thin air, or a particularly optimistic tea leaf reading. It resides in Regeneron’s pipeline – a collection of 26 candidates currently undergoing late-stage trials. Which, to put it mildly, is a lot of trials. One hopes they have a good system for keeping track of everything. Imagine the paperwork.)

What Does Regeneron Actually Do?

Regeneron, it turns out, develops treatments for a bewildering array of ailments. Eye diseases, allergic reactions, cancer, cardiovascular problems, neurological conditions, and even rare diseases – they seem to cover a great deal of ground. Their current flagship therapy, Dupixent, generated $17.8 billion in revenue in 2025. An astonishing amount of money, when you consider it’s derived from alleviating discomfort. (One can’t help but wonder if there’s a moral calculation involved somewhere.) It recently received its ninth approval, specifically for allergic fungal rhinosinusitis – a chronic sinus infection. Which, let’s be honest, sounds thoroughly unpleasant.)

Regeneron shares the profits from Dupixent with Sanofi, but the arrangement is shifting. Once a certain reimbursement obligation is met (sometime this year), Regeneron will receive a larger share. It’s a bit like a cosmic game of financial musical chairs. (One hopes they have a comfortable chair.)

Beyond Dupixent, Regeneron boasts two other blockbuster drugs: Eylea, for eye conditions, and Libtayo, a cancer treatment. They have a pipeline of 45 therapies, including existing drugs being investigated for new applications. (It’s a bit like endlessly rearranging the deck chairs on the Titanic, but with the hope of discovering a previously unknown life raft.) Leonard Schleifer, Regeneron’s President and CEO, anticipates at least four FDA approvals this year. (One suspects he has a very large calendar.) This doesn’t include garetosmab, a biologic for fibrodysplasia ossificans progressiva – a rare genetic disorder where soft tissue turns into bone. (A truly alarming prospect.)

Plenty of Financial Security (and Another Blockbuster on the Horizon)

In 2025, Regeneron’s revenue rose 1% to $14.3 billion, with earnings per share increasing 8% to $41.48. Eylea brought in $4.4 billion (down 27%), while Libtayo reached $1.5 billion (up 8%). However, these figures may soon be eclipsed by olatorepatide – a GLP-1 weight loss and diabetes candidate. (The quest for the perfect waistline continues, apparently.)

Trials conducted by Regeneron’s Chinese partner, Hansoh, suggest olatorepatide’s efficacy is comparable to Eli Lilly’s tirzepatide (marketed as Mounjaro and Zepbound). Crucially, it may be easier on the stomach. Hansoh reported lower rates of gastrointestinal distress and fewer treatment discontinuations. (A significant advantage, if one values a peaceful digestive system.) Eli Lilly booked $36.5 billion in sales from Mounjaro and Zepbound in 2025. If olatorepatide receives regulatory approval, it could spark rapid revenue growth for Regeneron. (The financial implications are, shall we say, substantial.)

Analysts predict olatorepatide could generate $14.8 billion in annual revenue by 2028 – exceeding Regeneron’s total revenue from last year. The weight-loss drug sector is expected to reach $23.6 billion by 2030, up from $4.2 billion in 2025. Based on this addition alone, Regeneron has the potential to be a two-bagger well before 2036 – and deliver multibagger gains to investors who buy shares now. (One should, of course, consult a financial advisor before making any investment decisions. And perhaps a cosmologist, just to be sure.)

Read More

2026-03-12 10:53